Latest News
Roche haemophilia data piles pressure on Shire
Hemlibra threatens to take market share from Advate
Takeda to cut IT, marketing and sales jobs after Shire merger
Takeda aiming for $1.4bn savings per year
More news
Key payer backs Ultragenyx’ rare rickets drug at $200,000 per year
Express Scripts’ Miller backs “responsible” price
Pacira CEO hopes for further expansion to US nerve block label
CEO wants “broad nerve block label” for Exparel
Biogen gets go-ahead for EU Humira launch in October
But deal with Samsung prevents US launch until mid-2023
Life sciences failing to keep pace with digital revolution – report
Focus on services, not products, report argues.
GSK left as sole bidder for Pfizer consumer health unit
GSK is left as sole bidder amid speculation that the sale is off.
Mundipharma to market Herceptin biosimilar in key EU markets
Mundipharma’s third biosimilar tie-up with Celltrion
Call for new restrictions on UK vaccine prices
Proposals also include fresh attack on drug prices
AstraZeneca spins out biotech to focus on autoimmune candidates
AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes.
AI specialists join Genomics England’s drug discovery alliance
Lantern Pharma, a pharma company which uses artificial intelligence to develop shelved oncology drugs has joined Genomics England’s groundbreaking industry partnership.
Tesaro and Roche to combine drugs in bladder cancer trials
Tesaro is to combine its PARP-inhibitor drug Zejula with Roche’s PD-L1 immunotherapy Tecentriq in clinical trials for metastatic bladder cancer.
Trulicity helps SGLT-2 patients lower blood sugar
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.
Eisai disappointed after NICE rejects earlier use for breast cancer drug
NICE says no to Halaven in second line breast cancer
FDA advisers reject new use for Pacira nerve block
Doubts over nerve blocker Exparel
